首页 > 最新文献

Journal of Nuclear Medicine最新文献

英文 中文
Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging? 新旧结合:我们能否弥合基于骨扫描的临床试验结果与现代前列腺癌症成像时代之间的差距?
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2023-11-01 Epub Date: 2023-08-17 DOI: 10.2967/jnumed.123.266025
Michal Eifer, Ramin Alipour, Michael S Hofman, Aravind S Ravi Kumar
{"title":"Out with the Old, in with the New: Can We Bridge the Gap Between Clinical Trial Results Based on Bone Scans and the Era of Modern Prostate Cancer Imaging?","authors":"Michal Eifer, Ramin Alipour, Michael S Hofman, Aravind S Ravi Kumar","doi":"10.2967/jnumed.123.266025","DOIUrl":"10.2967/jnumed.123.266025","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10018204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [68Ga]Ga-FAPI-46 PET-Positive and [18F]FDG PET-Negative. 口腔鳞状细胞癌引起的阻塞性唾液腺炎:[68Ga]Ga-FAPI-46 PET阳性和[18F]FDG PET阴性。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-05-25 DOI: 10.2967/jnumed.123.265498
Peter George Maliha, Abie H Mendelsohn, Johannes Czernin, Taylor Howard, Jeremie Calais, Masatoshi Hotta
{"title":"Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [<sup>68</sup>Ga]Ga-FAPI-46 PET-Positive and [<sup>18</sup>F]FDG PET-Negative.","authors":"Peter George Maliha,&nbsp;Abie H Mendelsohn,&nbsp;Johannes Czernin,&nbsp;Taylor Howard,&nbsp;Jeremie Calais,&nbsp;Masatoshi Hotta","doi":"10.2967/jnumed.123.265498","DOIUrl":"10.2967/jnumed.123.265498","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9522832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HER2-Low Breast Cancer Can Be Visualized by HER2 PET. HER2低乳腺癌症可通过HER2 PET显示。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-09-14 DOI: 10.2967/jnumed.123.266101
Renske Altena, Siri Af Burén, Thuy Tran, Rimma Axelsson
{"title":"HER2-Low Breast Cancer Can Be Visualized by HER2 PET.","authors":"Renske Altena,&nbsp;Siri Af Burén,&nbsp;Thuy Tran,&nbsp;Rimma Axelsson","doi":"10.2967/jnumed.123.266101","DOIUrl":"10.2967/jnumed.123.266101","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10246110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Total-Body Multiparametric PET Quantification of 18F-FDG Delivery and Metabolism in the Study of Coronavirus Disease 2019 Recovery. 2019冠状病毒疾病康复研究中18F-FDG递送和代谢的全身多参数PET定量。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-08-17 DOI: 10.2967/jnumed.123.265723
Yiran Wang, Lorenzo Nardo, Benjamin A Spencer, Yasser G Abdelhafez, Elizabeth J Li, Negar Omidvari, Abhijit J Chaudhari, Ramsey D Badawi, Terry Jones, Simon R Cherry, Guobao Wang

Conventional whole-body static 18F-FDG PET imaging provides a semiquantitative evaluation of overall glucose metabolism without insight into the specific transport and metabolic steps. Here we demonstrate the ability of total-body multiparametric 18F-FDG PET to quantitatively evaluate glucose metabolism using macroparametric quantification and assess specific glucose delivery and phosphorylation processes using microparametric quantification for studying recovery from coronavirus disease 2019 (COVID-19). Methods: The study included 13 healthy subjects and 12 recovering COVID-19 subjects within 8 wk of confirmed diagnosis. Each subject had a 1-h dynamic 18F-FDG scan on the uEXPLORER total-body PET/CT system. Semiquantitative SUV and the SUV ratio relative to blood (SUVR) were calculated for different organs to measure glucose utilization. Tracer kinetic modeling was performed to quantify the microparametric blood-to-tissue 18F-FDG delivery rate [Formula: see text] and the phosphorylation rate k 3, as well as the macroparametric 18F-FDG net influx rate ([Formula: see text]). Statistical tests were performed to examine differences between healthy subjects and recovering COVID-19 subjects. The effect of COVID-19 vaccination was also investigated. Results: We detected no significant difference in lung SUV but significantly higher lung SUVR and [Formula: see text] in COVID-19 recovery, indicating improved sensitivity of kinetic quantification for detecting the difference in glucose metabolism. A significant difference was also observed in the lungs with the phosphorylation rate k 3 but not with [Formula: see text], which suggests that glucose phosphorylation, rather than glucose delivery, drives the observed difference of glucose metabolism. Meanwhile, there was no or little difference in bone marrow 18F-FDG metabolism measured with SUV, SUVR, and [Formula: see text] but a significantly higher bone marrow [Formula: see text] in the COVID-19 group, suggesting a difference in glucose delivery. Vaccinated COVID-19 subjects had a lower lung [Formula: see text] and a higher spleen [Formula: see text] than unvaccinated COVID-19 subjects. Conclusion: Higher lung glucose metabolism and bone marrow glucose delivery were observed with total-body multiparametric 18F-FDG PET in recovering COVID-19 subjects than in healthy subjects, implying continued inflammation during recovery. Vaccination demonstrated potential protection effects. Total-body multiparametric PET of 18F-FDG can provide a more sensitive tool and more insights than conventional whole-body static 18F-FDG imaging to evaluate metabolic changes in systemic diseases such as COVID-19.

常规的全身静态18F-FDG PET成像提供了对整体葡萄糖代谢的半定量评估,而没有深入了解具体的转运和代谢步骤。在这里,我们证明了全身多参数18F-FDG PET的能力,即使用宏观参数定量来定量评估葡萄糖代谢,并使用微观参数定量来评估特定的葡萄糖递送和磷酸化过程,以研究2019冠状病毒病(新冠肺炎)的康复。方法:该研究包括13名健康受试者和12名新冠肺炎康复受试者,他们在确诊后8周内。每个受试者在uEXPLORER全身PET/CT系统上进行1小时动态18F-FDG扫描。计算不同器官的半定量SUV和SUV相对于血液的比率(SUVR),以测量葡萄糖利用率。进行示踪剂动力学建模以量化微参数血液至组织18F-FDG递送速率[公式:见正文]和磷酸化速率K3,以及大参数18F-FDG净流入速率([公式:参见正文])。进行统计测试,以检查健康受试者与新冠肺炎康复受试者之间的差异。还对新冠肺炎疫苗接种的效果进行了调查。结果:我们检测到肺SUV没有显著差异,但在新冠肺炎恢复中,肺SUVR和[公式:见正文]显著升高,表明动力学定量检测葡萄糖代谢差异的敏感性提高。在肺中也观察到磷酸化率k3的显著差异,但在[公式:见正文]中没有观察到,这表明葡萄糖磷酸化而不是葡萄糖输送驱动了观察到的葡萄糖代谢差异。同时,SUV、SUVR和[公式:见正文]测量的骨髓18F-FDG代谢没有或几乎没有差异,但新冠肺炎组的骨髓[公式:参见正文]显著较高,表明葡萄糖输送存在差异。与未接种新冠肺炎受试者相比,接种新冠肺炎受试者的肺较低[公式:见正文],脾较高[公式:参见正文]。结论:与健康受试者相比,全身多参数18F-FDG PET在新冠肺炎康复受试者中观察到更高的肺葡萄糖代谢和骨髓葡萄糖输送,这意味着在康复过程中炎症持续。疫苗接种显示出潜在的保护作用。18F-FDG的全身多参数PET可以提供比常规全身静态18F-FDG成像更灵敏的工具和更多的见解,以评估系统性疾病(如新冠肺炎)的代谢变化。
{"title":"Total-Body Multiparametric PET Quantification of <sup>18</sup>F-FDG Delivery and Metabolism in the Study of Coronavirus Disease 2019 Recovery.","authors":"Yiran Wang, Lorenzo Nardo, Benjamin A Spencer, Yasser G Abdelhafez, Elizabeth J Li, Negar Omidvari, Abhijit J Chaudhari, Ramsey D Badawi, Terry Jones, Simon R Cherry, Guobao Wang","doi":"10.2967/jnumed.123.265723","DOIUrl":"10.2967/jnumed.123.265723","url":null,"abstract":"<p><p>Conventional whole-body static <sup>18</sup>F-FDG PET imaging provides a semiquantitative evaluation of overall glucose metabolism without insight into the specific transport and metabolic steps. Here we demonstrate the ability of total-body multiparametric <sup>18</sup>F-FDG PET to quantitatively evaluate glucose metabolism using macroparametric quantification and assess specific glucose delivery and phosphorylation processes using microparametric quantification for studying recovery from coronavirus disease 2019 (COVID-19). <b>Methods:</b> The study included 13 healthy subjects and 12 recovering COVID-19 subjects within 8 wk of confirmed diagnosis. Each subject had a 1-h dynamic <sup>18</sup>F-FDG scan on the uEXPLORER total-body PET/CT system. Semiquantitative SUV and the SUV ratio relative to blood (SUVR) were calculated for different organs to measure glucose utilization. Tracer kinetic modeling was performed to quantify the microparametric blood-to-tissue <sup>18</sup>F-FDG delivery rate [Formula: see text] and the phosphorylation rate <i>k</i> <sub>3</sub>, as well as the macroparametric <sup>18</sup>F-FDG net influx rate ([Formula: see text]). Statistical tests were performed to examine differences between healthy subjects and recovering COVID-19 subjects. The effect of COVID-19 vaccination was also investigated. <b>Results:</b> We detected no significant difference in lung SUV but significantly higher lung SUVR and [Formula: see text] in COVID-19 recovery, indicating improved sensitivity of kinetic quantification for detecting the difference in glucose metabolism. A significant difference was also observed in the lungs with the phosphorylation rate <i>k</i> <sub>3</sub> but not with [Formula: see text], which suggests that glucose phosphorylation, rather than glucose delivery, drives the observed difference of glucose metabolism. Meanwhile, there was no or little difference in bone marrow <sup>18</sup>F-FDG metabolism measured with SUV, SUVR, and [Formula: see text] but a significantly higher bone marrow [Formula: see text] in the COVID-19 group, suggesting a difference in glucose delivery. Vaccinated COVID-19 subjects had a lower lung [Formula: see text] and a higher spleen [Formula: see text] than unvaccinated COVID-19 subjects. <b>Conclusion:</b> Higher lung glucose metabolism and bone marrow glucose delivery were observed with total-body multiparametric <sup>18</sup>F-FDG PET in recovering COVID-19 subjects than in healthy subjects, implying continued inflammation during recovery. Vaccination demonstrated potential protection effects. Total-body multiparametric PET of <sup>18</sup>F-FDG can provide a more sensitive tool and more insights than conventional whole-body static <sup>18</sup>F-FDG imaging to evaluate metabolic changes in systemic diseases such as COVID-19.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10498200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease. 通过PET检测IL12/23p40显示炎症性肠病。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-07-20 DOI: 10.2967/jnumed.123.265649
Farzaneh Rezazadeh, Nicholas Ramos, Allen-Dexter Saliganan, Najeeb Al-Hallak, Kang Chen, Bashar Mohamad, Wendy N Wiesend, Nerissa T Viola

Inflammatory bowel disease (IBD), which includes both Crohn disease and ulcerative colitis, is a relapsing inflammatory disease of the gastrointestinal tract. Long-term chronic inflammatory conditions elevate the patient's risk of colorectal cancer (CRC). Currently, diagnosis requires endoscopy with biopsy. This procedure is invasive and requires a bowel-preparatory regimen, adding to patient burden. Interleukin 12 (IL12) and interleukin 23 (IL23) play key roles in inflammation, especially in the pathogenesis of IBD, and are established therapeutic targets. We propose that imaging of IL12/23 and its p40 subunit in IBD via immuno-PET potentially provides a new noninvasive diagnostic approach. Methods: Our aim was to investigate the potential of immuno-PET to image inflammation in a chemically induced mouse model of colitis using dextran sodium sulfate by targeting IL12/23p40 with a 89Zr-radiolabeled anti-IL12/23p40 antibody. Results: High uptake of the IL12/23p40 immuno-PET agent was exhibited by dextran sodium sulfate-administered mice, and this uptake correlated with increased IL12/23p40 present in the sera. Competitive binding studies confirmed the specificity of the radiotracer for IL12/23p40 in the gastrointestinal tract. Conclusion: These promising results demonstrate the utility of this radiotracer as an imaging biomarker of IBD. Moreover, IL12/23p40 immuno-PET can potentially guide treatment decisions for IBD management.

炎症性肠病(IBD)是一种复发性胃肠道炎症性疾病,包括克罗恩病和溃疡性结肠炎。长期慢性炎症性疾病会增加患者患癌症(CRC)的风险。目前,诊断需要内窥镜检查和活检。这种手术具有侵入性,需要肠道准备方案,增加了患者负担。白介素12(IL12)和白介素23(IL23)在炎症中起着关键作用,尤其是在IBD的发病机制中,是已确定的治疗靶点。我们提出,通过免疫PET对IBD中IL12/23及其p40亚基进行成像可能提供一种新的无创诊断方法。方法:我们的目的是通过用89Zr放射性标记的抗IL12/23p40抗体靶向IL12/23p40,研究免疫PET在使用右旋糖酐硫酸钠的化学诱导的结肠炎小鼠模型中成像炎症的潜力。结果:右旋糖酐硫酸钠给药的小鼠表现出对IL12/23p40免疫PET剂的高摄取,并且这种摄取与血清中存在的IL12/23p40的增加相关。竞争性结合研究证实了放射性示踪剂在胃肠道中对IL12/23p40的特异性。结论:这些有希望的结果证明了这种放射性示踪剂作为IBD的成像生物标志物的实用性。此外,IL12/23p40免疫PET可以潜在地指导IBD管理的治疗决策。
{"title":"Detection of IL12/23p40 via PET Visualizes Inflammatory Bowel Disease.","authors":"Farzaneh Rezazadeh, Nicholas Ramos, Allen-Dexter Saliganan, Najeeb Al-Hallak, Kang Chen, Bashar Mohamad, Wendy N Wiesend, Nerissa T Viola","doi":"10.2967/jnumed.123.265649","DOIUrl":"10.2967/jnumed.123.265649","url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD), which includes both Crohn disease and ulcerative colitis, is a relapsing inflammatory disease of the gastrointestinal tract. Long-term chronic inflammatory conditions elevate the patient's risk of colorectal cancer (CRC). Currently, diagnosis requires endoscopy with biopsy. This procedure is invasive and requires a bowel-preparatory regimen, adding to patient burden. Interleukin 12 (IL12) and interleukin 23 (IL23) play key roles in inflammation, especially in the pathogenesis of IBD, and are established therapeutic targets. We propose that imaging of IL12/23 and its p40 subunit in IBD via immuno-PET potentially provides a new noninvasive diagnostic approach. <b>Methods:</b> Our aim was to investigate the potential of immuno-PET to image inflammation in a chemically induced mouse model of colitis using dextran sodium sulfate by targeting IL12/23p40 with a <sup>89</sup>Zr-radiolabeled anti-IL12/23p40 antibody. <b>Results:</b> High uptake of the IL12/23p40 immuno-PET agent was exhibited by dextran sodium sulfate-administered mice, and this uptake correlated with increased IL12/23p40 present in the sera. Competitive binding studies confirmed the specificity of the radiotracer for IL12/23p40 in the gastrointestinal tract. <b>Conclusion:</b> These promising results demonstrate the utility of this radiotracer as an imaging biomarker of IBD. Moreover, IL12/23p40 immuno-PET can potentially guide treatment decisions for IBD management.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10203981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Total-Body Perfusion Imaging with [11C]-Butanol. [11C]-丁醇全身灌注成像。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-08-31 DOI: 10.2967/jnumed.123.265659
Elizabeth J Li, Javier E López, Benjamin A Spencer, Yasser Abdelhafez, Ramsey D Badawi, Guobao Wang, Simon R Cherry

Tissue perfusion can be affected by physiology or disease. With the advent of total-body PET, quantitative measurement of perfusion across the entire body is possible. [11C]-butanol is a perfusion tracer with a superior extraction fraction compared with [15O]-water and [13N]-ammonia. To develop the methodology for total-body perfusion imaging, a pilot study using [11C]-butanol on the uEXPLORER total-body PET/CT scanner was conducted. Methods: Eight participants (6 healthy volunteers and 2 patients with peripheral vascular disease [PVD]) were injected with a bolus of [11C]-butanol and underwent 30-min dynamic acquisitions. Three healthy volunteers underwent repeat studies at rest (baseline) to assess test-retest reproducibility; 1 volunteer underwent paired rest and cold pressor test (CPT) studies. Changes in perfusion were measured in the paired rest-CPT study. For PVD patients, local changes in perfusion were investigated and correlated with patient medical history. Regional and parametric kinetic analysis methods were developed using a 1-tissue compartment model and leading-edge delay correction. Results: Estimated baseline perfusion values ranged from 0.02 to 1.95 mL·min-1·cm-3 across organs. Test-retest analysis showed that repeat baseline perfusion measurements were highly correlated (slope, 0.99; Pearson r = 0.96, P < 0.001). For the CPT subject, the largest regional increases were in skeletal muscle (psoas, 142%) and the myocardium (64%). One of the PVD patients showed increased collateral vessel growth in the calf because of a peripheral stenosis. Comorbidities including myocardial infarction, hypothyroidism, and renal failure were correlated with variations in organ-specific perfusion. Conclusion: This pilot study demonstrates the ability to obtain reproducible measurements of total-body perfusion using [11C]-butanol. The methods are sensitive to local perturbations in flow because of physiologic stressors and disease.

组织灌注可能受到生理学或疾病的影响。随着全身PET的出现,全身灌注的定量测量成为可能。[11C]-丁醇是一种灌注示踪剂,与[15O]-水和[13N]-氨相比,具有更好的提取率。为了开发全身灌注成像的方法,在uEXPLORER全身PET/CT扫描仪上使用[11C]-丁醇进行了一项初步研究。方法:8名参与者(6名健康志愿者和2名外周血管病患者)注射[11C]-丁醇,并进行30分钟的动态采集。三名健康志愿者在休息时(基线)接受了重复研究,以评估重新测试的再现性;1名志愿者接受了配对休息和冷加压试验(CPT)研究。在配对静息CPT研究中测量灌注的变化。对于PVD患者,研究局部灌注变化,并将其与患者病史相关联。区域和参数动力学分析方法是使用1-组织室模型和前沿延迟校正开发的。结果:估计的基线灌注值范围为0.02至1.95 mL·min-1·cm-3。测试-再测试分析显示,重复基线灌注测量高度相关(斜率,0.99;Pearson r=0.96,P<0.001)。对于CPT受试者,最大的区域性增加发生在骨骼肌(腰大肌,142%)和心肌(64%)。其中一名PVD患者显示,由于外周狭窄,小腿侧支血管生长增加。合并症包括心肌梗死、甲状腺功能减退和肾功能衰竭与器官特异性灌注的变化相关。结论:该初步研究证明了使用[11C]-丁醇获得可重复测量全身灌注的能力。由于生理压力源和疾病,这些方法对血流中的局部扰动很敏感。
{"title":"Total-Body Perfusion Imaging with [<sup>11</sup>C]-Butanol.","authors":"Elizabeth J Li, Javier E López, Benjamin A Spencer, Yasser Abdelhafez, Ramsey D Badawi, Guobao Wang, Simon R Cherry","doi":"10.2967/jnumed.123.265659","DOIUrl":"10.2967/jnumed.123.265659","url":null,"abstract":"<p><p>Tissue perfusion can be affected by physiology or disease. With the advent of total-body PET, quantitative measurement of perfusion across the entire body is possible. [<sup>11</sup>C]-butanol is a perfusion tracer with a superior extraction fraction compared with [<sup>15</sup>O]-water and [<sup>13</sup>N]-ammonia. To develop the methodology for total-body perfusion imaging, a pilot study using [<sup>11</sup>C]-butanol on the uEXPLORER total-body PET/CT scanner was conducted. <b>Methods:</b> Eight participants (6 healthy volunteers and 2 patients with peripheral vascular disease [PVD]) were injected with a bolus of [<sup>11</sup>C]-butanol and underwent 30-min dynamic acquisitions. Three healthy volunteers underwent repeat studies at rest (baseline) to assess test-retest reproducibility; 1 volunteer underwent paired rest and cold pressor test (CPT) studies. Changes in perfusion were measured in the paired rest-CPT study. For PVD patients, local changes in perfusion were investigated and correlated with patient medical history. Regional and parametric kinetic analysis methods were developed using a 1-tissue compartment model and leading-edge delay correction. <b>Results:</b> Estimated baseline perfusion values ranged from 0.02 to 1.95 mL·min<sup>-1</sup>·cm<sup>-3</sup> across organs. Test-retest analysis showed that repeat baseline perfusion measurements were highly correlated (slope, 0.99; Pearson <i>r</i> = 0.96, <i>P</i> < 0.001). For the CPT subject, the largest regional increases were in skeletal muscle (psoas, 142%) and the myocardium (64%). One of the PVD patients showed increased collateral vessel growth in the calf because of a peripheral stenosis. Comorbidities including myocardial infarction, hypothyroidism, and renal failure were correlated with variations in organ-specific perfusion. <b>Conclusion:</b> This pilot study demonstrates the ability to obtain reproducible measurements of total-body perfusion using [<sup>11</sup>C]-butanol. The methods are sensitive to local perturbations in flow because of physiologic stressors and disease.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study. 一种基于前列腺特异性膜抗原PET的方法改进对格里森1级前列腺癌症的诊断:一项多中心回顾性研究。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-08-31 DOI: 10.2967/jnumed.122.265001
Jingliang Zhang, Fei Kang, Jie Gao, Jianhua Jiao, Zhiyong Quan, Shuaijun Ma, Yu Li, Shikuan Guo, Zeyu Li, Yuming Jing, Keying Zhang, Fa Yang, Donghui Han, Weihong Wen, Jing Zhang, Jing Ren, Jing Wang, Hongqian Guo, Weijun Qin

The preoperative Gleason grade group (GG) from transrectal ultrasound-guided prostate biopsy is crucial for treatment decisions but may underestimate the postoperative GG and miss clinically significant prostate cancer (csPCa), particularly in patients with biopsy GG1. In such patients, an SUVmax of at least 12 has 100% specificity for detecting csPCa. In patients with an SUVmax of less than 12, we aimed to develop a model to improve the diagnostic accuracy of csPCa. Methods: The study retrospectively included 56 prostate cancer patients with transrectal ultrasound-guided biopsy GG1 and an SUVmax of less than 12 from 2 tertiary hospitals. All [68Ga]Ga-PSMA-HBED-CC PET scans were centrally reviewed in Xijing Hospital. A deep learning model was used to evaluate the overlap of SUVmax (size scale, 3 cm) and the level of Gleason pattern (size scale, 500 μm). A diagnostic model was developed using the PRIMARY score and SUVmax, and its discriminative performance and clinical utility were compared with other methods. The 5-fold cross-validation (repeated 1,000 times) was used for internal validation. Results: In patients with GG1 and an SUVmax of less than 12, significant prostate-specific membrane antigen (PSMA) histochemical score (H-score) H-score overlap occurred among benign gland, Gleason pattern 3, and Gleason pattern 4 lesions, causing SUVmax overlap between csPCa and non-csPCa. The model of 10 × PRIMARY score + 2 × SUVmax exhibited a higher area under the curve (AUC, 0.8359; 95% CI, 0.7233-0.9484) than that found using only the SUVmax (AUC, 0.7353; P = 0.048) or PRIMARY score (AUC, 0.7257; P = 0.009) for the cohort and a higher AUC (0.8364; 95% CI, 0.7114-0.9614) than that found using only the Prostate Imaging Reporting and Data System (PI-RADS) score of 5-4 versus 3-1 (AUC, 0.7036; P = 0.149) and the PI-RADS score of 5-3 versus 2-1 (AUC, 0.6373; P = 0.014) for a subgroup. The model reduced the misdiagnosis of the PI-RADS score of 5-4 versus 3-1 by 78.57% (11/14) and the PI-RADS score of 5-3 versus 2-1 by 77.78% (14/18). The internal validation showed that the mean 5-fold cross-validated AUC was 0.8357 (95% CI, 0.8357-0.8358). Conclusion: We preliminarily suggest that the model of 10 × PRIMARY score + 2 × SUVmax may enhance the diagnostic accuracy of csPCa in patients with biopsy GG1 and an SUVmax of less than 12 by maximizing PSMA information use, reducing the misdiagnosis of the PI-RADS score, and thereby aiding in making appropriate treatment decisions.

经直肠超声引导前列腺活组织检查的术前Gleason分级组(GG)对治疗决策至关重要,但可能低估术后GG并错过临床意义重大的前列腺癌症(csPCa),尤其是在活组织检查GG1的患者中。在这类患者中,至少12的SUVmax对检测csPCa具有100%的特异性。在SUVmax小于12的患者中,我们旨在开发一个模型来提高csPCa的诊断准确性。方法:回顾性分析了来自2家三级医院的56例前列腺癌癌症患者,经直肠超声引导GG1活检,SUVmax小于12。所有[68Ga]Ga-PSMA HBED CC PET扫描均在西京医院进行集中审查。使用深度学习模型来评估SUVmax的重叠(尺寸尺度,3 cm)和Gleason图案的水平(尺寸尺度,500 μm)。使用PRIMARY评分和SUVmax建立了诊断模型,并将其判别性能和临床实用性与其他方法进行了比较。内部验证采用5次交叉验证(重复1000次)。结果:在GG1和SUVmax小于12的患者中,良性腺体、Gleason模式3和Gleason类型4病变之间出现显著的前列腺特异性膜抗原(PSMA)组织化学评分(H核)H核重叠,导致csPCa和非csPCa之间的SUVmax重叠。10×PRIMARY评分+2×SUVmax的模型的曲线下面积(AUC,0.8359;95%CI,0.7233-0.9484)高于仅使用队列的SUVmax(AUC;0.7353;P=0.048)或PRIMARY得分(AUC:0.7257;P=0.009)的模型,并且AUC(0.8364;95%CI:0.7114-0.9614)高于仅用前列腺成像报告和数据系统(PI-RADS)评分5-4的模型3-1(AUC,0.7036;P=0.149),并且亚组的PI-RADS评分为5-3对2-1(AUC;0.6373;P=0.014)。该模型将5-4分对3-1分的PI-RADS分的误诊率降低了78.57%(11/14),将5-3分对2-1分的PI-RADS分的误判率降低了77.78%(14/18)。内部验证显示,平均5倍交叉验证AUC为0.8357(95%CI,0.8357-0.8358)。结论:我们初步认为,10×PRIMARY评分+2×SUVmax的模型可以通过最大限度地利用PSMA信息,减少PI-RADS评分的误诊,提高csPCa对活检GG1和SUVmax小于12的患者的诊断准确性,从而有助于做出适当的治疗决定。
{"title":"A Prostate-Specific Membrane Antigen PET-Based Approach for Improved Diagnosis of Prostate Cancer in Gleason Grade Group 1: A Multicenter Retrospective Study.","authors":"Jingliang Zhang,&nbsp;Fei Kang,&nbsp;Jie Gao,&nbsp;Jianhua Jiao,&nbsp;Zhiyong Quan,&nbsp;Shuaijun Ma,&nbsp;Yu Li,&nbsp;Shikuan Guo,&nbsp;Zeyu Li,&nbsp;Yuming Jing,&nbsp;Keying Zhang,&nbsp;Fa Yang,&nbsp;Donghui Han,&nbsp;Weihong Wen,&nbsp;Jing Zhang,&nbsp;Jing Ren,&nbsp;Jing Wang,&nbsp;Hongqian Guo,&nbsp;Weijun Qin","doi":"10.2967/jnumed.122.265001","DOIUrl":"10.2967/jnumed.122.265001","url":null,"abstract":"<p><p>The preoperative Gleason grade group (GG) from transrectal ultrasound-guided prostate biopsy is crucial for treatment decisions but may underestimate the postoperative GG and miss clinically significant prostate cancer (csPCa), particularly in patients with biopsy GG1. In such patients, an SUV<sub>max</sub> of at least 12 has 100% specificity for detecting csPCa. In patients with an SUV<sub>max</sub> of less than 12, we aimed to develop a model to improve the diagnostic accuracy of csPCa. <b>Methods:</b> The study retrospectively included 56 prostate cancer patients with transrectal ultrasound-guided biopsy GG1 and an SUV<sub>max</sub> of less than 12 from 2 tertiary hospitals. All [<sup>68</sup>Ga]Ga-PSMA-HBED-CC PET scans were centrally reviewed in Xijing Hospital. A deep learning model was used to evaluate the overlap of SUV<sub>max</sub> (size scale, 3 cm) and the level of Gleason pattern (size scale, 500 μm). A diagnostic model was developed using the PRIMARY score and SUV<sub>max</sub>, and its discriminative performance and clinical utility were compared with other methods. The 5-fold cross-validation (repeated 1,000 times) was used for internal validation. <b>Results:</b> In patients with GG1 and an SUV<sub>max</sub> of less than 12, significant prostate-specific membrane antigen (PSMA) histochemical score (H-score) H-score overlap occurred among benign gland, Gleason pattern 3, and Gleason pattern 4 lesions, causing SUV<sub>max</sub> overlap between csPCa and non-csPCa. The model of 10 × PRIMARY score + 2 × SUV<sub>max</sub> exhibited a higher area under the curve (AUC, 0.8359; 95% CI, 0.7233-0.9484) than that found using only the SUV<sub>max</sub> (AUC, 0.7353; <i>P</i> = 0.048) or PRIMARY score (AUC, 0.7257; <i>P</i> = 0.009) for the cohort and a higher AUC (0.8364; 95% CI, 0.7114-0.9614) than that found using only the Prostate Imaging Reporting and Data System (PI-RADS) score of 5-4 versus 3-1 (AUC, 0.7036; <i>P</i> = 0.149) and the PI-RADS score of 5-3 versus 2-1 (AUC, 0.6373; <i>P</i> = 0.014) for a subgroup. The model reduced the misdiagnosis of the PI-RADS score of 5-4 versus 3-1 by 78.57% (11/14) and the PI-RADS score of 5-3 versus 2-1 by 77.78% (14/18). The internal validation showed that the mean 5-fold cross-validated AUC was 0.8357 (95% CI, 0.8357-0.8358). <b>Conclusion:</b> We preliminarily suggest that the model of 10 × PRIMARY score + 2 × SUV<sub>max</sub> may enhance the diagnostic accuracy of csPCa in patients with biopsy GG1 and an SUV<sub>max</sub> of less than 12 by maximizing PSMA information use, reducing the misdiagnosis of the PI-RADS score, and thereby aiding in making appropriate treatment decisions.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High Tumor Uptake on 18F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d'étude des Tumeurs Endocrines and ENDOCAN-RENATEN Network. 18F-FDOPA PET/CT上的高肿瘤摄取表明转移性中肠神经内分泌肿瘤患者的预后较差:来自肿瘤内分泌组和内分泌网络的一项研究。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-08-31 DOI: 10.2967/jnumed.123.265584
Ophélie De Rycke, Marine Perrier, Éric Ouvrard, Clément Mennetrey, Choaib Lachachi, Aurélie Bando-Delaunay, David Morland, Bernard Goichot, David Taieb, Thomas Walter, Guillaume Cadiot, Jérôme Cros, Olivia Hentic, Philippe Ruszniewski, Rachida Lebtahi, Alessio Imperiale, Louis de Mestier
Visual Abstract PET/CT with 6-18F-fluoro-l-dopa (18F-FDOPA) has high diagnostic performance for midgut neuroendocrine tumors (NETs). We explored the prognostic role of 18F-FDOPA PET/CT uptake in metastatic midgut NETs. Methods: We included, in a test cohort (n = 166) and a full external validation cohort (n = 86), all consecutive patients with metastatic midgut NETs who underwent 18F-FDOPA PET/CT in 5 expert centers from 2010 to 2021. We measured the maximal uptake (SUVmax and SUVpeak) of the tumor and nontumor liver on each 18F-FDOPA PET/CT scan. We measured overall survival (OS) from the time of PET/CT and assessed prognostic factors using Kaplan–Meier and multivariable Cox proportional-hazards analyses in the test cohort, with replication in the validation cohort. Results: Patients had similar characteristics in both cohorts. In the test cohort, median follow-up was 60.3 mo. Patients with an SUVpeak tumor-to-liver (T/L) ratio of more than 4.2 had significantly shorter survival than those with a ratio of 4.2 or less (P = 0.01), with a 5-y OS rate of 74.1% ± 4.5% versus 95% ± 3.4%, respectively. On multivariable analysis, an SUVpeak T/L ratio of more than 4.2 remained associated with shorter OS (hazard ratio, 2.30; 95% CI, 1.02–5.22; P = 0.046) after adjustment for age, grade, number of previous lines, number of metastatic sites, and presence of carcinoid syndrome. In the validation cohort, the 5-y OS rate was 100% versus 57.8% ± 12.5% in patients with an SUVpeak T/L ratio ≤ 4.2 or > 4.2, respectively (P = 0.075). An increasing SUVpeak T/L ratio over time tended to have a pejorative prognostic impact. Conclusion: Tumor uptake on 18F-FDOPA PET/CT is an independent prognostic factor in patients with metastatic midgut NETs.
6-18F-FDOPA的PET/CT对中肠神经内分泌肿瘤有较高的诊断价值。我们探讨了18F-FDOPA PET/CT摄取在转移性中肠NETs中的预后作用。方法:我们在一个测试队列(n=166)和一个完整的外部验证队列(n=86)中纳入了2010年至2021年在5个专家中心接受18F-FDOPA PET/CT的所有连续的转移性中肠NETs患者。我们在每次18F-FDOPA PET/CT扫描中测量了肿瘤和非肿瘤肝脏的最大摄取量(SUVmax和SUVpeak)。我们在测试队列中使用Kaplan-Meier和多变量Cox比例风险分析测量了PET/CT时的总生存率(OS),并在验证队列中进行了复制,评估了预后因素。结果:两组患者的特征相似。在试验队列中,中位随访为60.3 mo.SUV峰值肿瘤与肝脏(T/L)比率大于4.2的患者的生存期明显短于比率为4.2或更低的患者(P=0.01),5-y OS率分别为74.1%±4.5%和95%±3.4%。在多变量分析中,在调整了年龄、级别、先前行数、转移部位数和类癌综合征的存在后,SUVpeak T/L比值超过4.2仍与较短的OS相关(危险比,2.30;95%CI,1.02-5.22;P=0.046)。在验证队列中,SUVpeak T/L比率≤4.2或>4.2的患者的5-y OS发生率分别为100%和57.8%±12.5%(P=0.075)。随着时间的推移,SUV峰值T/L比率的增加往往会对预后产生不利影响。结论:18F-FDOPA PET/CT对肿瘤的摄取是转移性中肠NETs患者的独立预后因素。
{"title":"High Tumor Uptake on <sup>18</sup>F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d'étude des Tumeurs Endocrines and ENDOCAN-RENATEN Network.","authors":"Ophélie De Rycke,&nbsp;Marine Perrier,&nbsp;Éric Ouvrard,&nbsp;Clément Mennetrey,&nbsp;Choaib Lachachi,&nbsp;Aurélie Bando-Delaunay,&nbsp;David Morland,&nbsp;Bernard Goichot,&nbsp;David Taieb,&nbsp;Thomas Walter,&nbsp;Guillaume Cadiot,&nbsp;Jérôme Cros,&nbsp;Olivia Hentic,&nbsp;Philippe Ruszniewski,&nbsp;Rachida Lebtahi,&nbsp;Alessio Imperiale,&nbsp;Louis de Mestier","doi":"10.2967/jnumed.123.265584","DOIUrl":"10.2967/jnumed.123.265584","url":null,"abstract":"Visual Abstract PET/CT with 6-18F-fluoro-l-dopa (18F-FDOPA) has high diagnostic performance for midgut neuroendocrine tumors (NETs). We explored the prognostic role of 18F-FDOPA PET/CT uptake in metastatic midgut NETs. Methods: We included, in a test cohort (n = 166) and a full external validation cohort (n = 86), all consecutive patients with metastatic midgut NETs who underwent 18F-FDOPA PET/CT in 5 expert centers from 2010 to 2021. We measured the maximal uptake (SUVmax and SUVpeak) of the tumor and nontumor liver on each 18F-FDOPA PET/CT scan. We measured overall survival (OS) from the time of PET/CT and assessed prognostic factors using Kaplan–Meier and multivariable Cox proportional-hazards analyses in the test cohort, with replication in the validation cohort. Results: Patients had similar characteristics in both cohorts. In the test cohort, median follow-up was 60.3 mo. Patients with an SUVpeak tumor-to-liver (T/L) ratio of more than 4.2 had significantly shorter survival than those with a ratio of 4.2 or less (P = 0.01), with a 5-y OS rate of 74.1% ± 4.5% versus 95% ± 3.4%, respectively. On multivariable analysis, an SUVpeak T/L ratio of more than 4.2 remained associated with shorter OS (hazard ratio, 2.30; 95% CI, 1.02–5.22; P = 0.046) after adjustment for age, grade, number of previous lines, number of metastatic sites, and presence of carcinoid syndrome. In the validation cohort, the 5-y OS rate was 100% versus 57.8% ± 12.5% in patients with an SUVpeak T/L ratio ≤ 4.2 or > 4.2, respectively (P = 0.075). An increasing SUVpeak T/L ratio over time tended to have a pejorative prognostic impact. Conclusion: Tumor uptake on 18F-FDOPA PET/CT is an independent prognostic factor in patients with metastatic midgut NETs.","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10185218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for 89Zr-Trastuzumab. 长轴与短轴视野免疫PET/CT:89Zr曲妥珠单抗的半定量评价。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-08-03 DOI: 10.2967/jnumed.123.265621
Philipp Mohr, Joyce van Sluis, Laura Providência, Johannes H van Snick, Marjolijn N Lub-de Hooge, Antoon T Willemsen, Andor W J M Glaudemans, Ronald Boellaard, Adriaan A Lammertsma, Adrienne H Brouwers, Charalampos Tsoumpas

The purpose of this study was to quantify any differences between the SUVs of 89Zr immuno-PET scans obtained using a PET/CT system with a long axial field of view (LAFOV; Biograph Vision Quadra) compared to a PET/CT system with a short axial field of view (SAFOV; Biograph Vision) and to evaluate how LAFOV PET scan duration affects image noise and SUV metrics. Methods: Five metastatic breast cancer patients were scanned consecutively on SAFOV and LAFOV PET/CT scanners. Four additional patients were scanned using only LAFOV PET/CT. Scans on both systems lasted approximately 30 min and were acquired 4 d after injection of 37 MBq of 89Zr-trastuzumab. LAFOV list-mode data were reprocessed to obtain images acquired using shorter scan durations (15, 10, 7.5, 5, and 3 min). Volumes of interest were placed in healthy tissues, and tumors were segmented semiautomatically to compare coefficients of variation and to perform Bland-Altman analysis on SUV metrics (SUVmax, SUVpeak, and SUVmean). Results: Using 30-min images, 2 commonly used lesion SUV metrics were higher for SAFOV than for LAFOV PET (SUVmax, 16.2% ± 13.4%, and SUVpeak, 10.1% ± 7.2%), whereas the SUVmean of healthy tissues showed minimal differences (0.7% ± 5.8%). Coefficients of variation in the liver derived from 30-min SAFOV PET were between those of 3- and 5-min LAFOV PET. The smallest SUVmax and SUVpeak differences between SAFOV and LAFOV were found for 3-min LAFOV PET. Conclusion: LAFOV 89Zr immuno-PET showed a lower SUVmax and SUVpeak than SAFOV because of lower image noise. LAFOV PET scan duration may be reduced at the expense of increasing image noise and bias in SUV metrics. Nevertheless, SUVpeak showed only minimal bias when reducing scan duration from 30 to 10 min.

本研究的目的是量化使用具有长轴视场的PET/CT系统(LAFOV;Biograph-Vision Quadra)获得的89Zr免疫PET扫描的SUV与具有短轴视场的PET/COT系统(SAFOV;Biograph-Vision)之间的任何差异,并评估LAFOV PET扫描持续时间如何影响图像噪声和SUV指标。方法:对5例转移性癌症患者在SAFOV和LAFOV PET/CT扫描仪上连续扫描。另外四名患者仅使用LAFOV PET/CT进行扫描。两个系统的扫描持续了大约30次 分钟,并在注射37MBq的89Zr曲妥珠单抗后4天获得。对LAFOV列表模式数据进行再处理,以获得使用较短扫描持续时间(15、10、7.5、5和3 分钟)。将感兴趣的体积放置在健康组织中,并半自动分割肿瘤,以比较变异系数,并对SUV指标(SUVmax、SUVpeak和SUVmean)进行Bland-Altman分析。结果:使用30分钟图像,SAFOV的2个常用病变SUV指标高于LAFOV PET(SUVmax,16.2%±13.4%,SUVpeak,10.1%±7.2%),而健康组织的SUVmean差异最小(0.7%±5.8%)。30分钟SAFOV PET得出的肝脏变异系数介于3分钟和5分钟LAFOV PET。对于3分钟的LAFOV PET,发现SAFOV和LAFOV之间的SUVmax和SUVpeak差异最小。结论:LAFOV 89Zr免疫PET显示出比SAFOV更低的SUVmax和SUVpeak,因为图像噪声更低。LAFOV PET扫描持续时间可以以增加图像噪声和SUV度量中的偏差为代价来减少。然而,当扫描持续时间从30减少到10时,SUVpeak只显示出最小的偏差 最小。
{"title":"Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for <sup>89</sup>Zr-Trastuzumab.","authors":"Philipp Mohr,&nbsp;Joyce van Sluis,&nbsp;Laura Providência,&nbsp;Johannes H van Snick,&nbsp;Marjolijn N Lub-de Hooge,&nbsp;Antoon T Willemsen,&nbsp;Andor W J M Glaudemans,&nbsp;Ronald Boellaard,&nbsp;Adriaan A Lammertsma,&nbsp;Adrienne H Brouwers,&nbsp;Charalampos Tsoumpas","doi":"10.2967/jnumed.123.265621","DOIUrl":"10.2967/jnumed.123.265621","url":null,"abstract":"<p><p>The purpose of this study was to quantify any differences between the SUVs of <sup>89</sup>Zr immuno-PET scans obtained using a PET/CT system with a long axial field of view (LAFOV; Biograph Vision Quadra) compared to a PET/CT system with a short axial field of view (SAFOV; Biograph Vision) and to evaluate how LAFOV PET scan duration affects image noise and SUV metrics. <b>Methods:</b> Five metastatic breast cancer patients were scanned consecutively on SAFOV and LAFOV PET/CT scanners. Four additional patients were scanned using only LAFOV PET/CT. Scans on both systems lasted approximately 30 min and were acquired 4 d after injection of 37 MBq of <sup>89</sup>Zr-trastuzumab. LAFOV list-mode data were reprocessed to obtain images acquired using shorter scan durations (15, 10, 7.5, 5, and 3 min). Volumes of interest were placed in healthy tissues, and tumors were segmented semiautomatically to compare coefficients of variation and to perform Bland-Altman analysis on SUV metrics (SUV<sub>max</sub>, SUV<sub>peak</sub>, and SUV<sub>mean</sub>). <b>Results:</b> Using 30-min images, 2 commonly used lesion SUV metrics were higher for SAFOV than for LAFOV PET (SUV<sub>max</sub>, 16.2% ± 13.4%, and SUV<sub>peak</sub>, 10.1% ± 7.2%), whereas the SUV<sub>mean</sub> of healthy tissues showed minimal differences (0.7% ± 5.8%). Coefficients of variation in the liver derived from 30-min SAFOV PET were between those of 3- and 5-min LAFOV PET. The smallest SUV<sub>max</sub> and SUV<sub>peak</sub> differences between SAFOV and LAFOV were found for 3-min LAFOV PET. <b>Conclusion:</b> LAFOV <sup>89</sup>Zr immuno-PET showed a lower SUV<sub>max</sub> and SUV<sub>peak</sub> than SAFOV because of lower image noise. LAFOV PET scan duration may be reduced at the expense of increasing image noise and bias in SUV metrics. Nevertheless, SUV<sub>peak</sub> showed only minimal bias when reducing scan duration from 30 to 10 min.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9936955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET. 回复:HER2低乳腺癌症可通过HER2 PET显示。
IF 9.3 1区 医学 Q1 Medicine Pub Date : 2023-11-01 Epub Date: 2023-09-14 DOI: 10.2967/jnumed.123.266490
Romain-David Seban
{"title":"Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET.","authors":"Romain-David Seban","doi":"10.2967/jnumed.123.266490","DOIUrl":"10.2967/jnumed.123.266490","url":null,"abstract":"","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":null,"pages":null},"PeriodicalIF":9.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10246117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Nuclear Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1